VIATRIS INC. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested
VIATRIS INC. (VTRS) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested of $300.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested · last filed 2026-08-06
- VIATRIS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2026-06-30 was $100.00K.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2026-03-31 was $200.00K, a 100.00% increase year-over-year.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2025-12-31 was $100.00K.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2025 was $200.00K, a 60.00% decline from fiscal 2024.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2024 was $500.00K, a 16.67% decline from fiscal 2023.
- VIATRIS INC. share-based compensation arrangement by share-based payment award, equity instruments other than options, aggregate intrinsic value, vested for fiscal 2023 was $600.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested 12 month |
|---|---|---|---|---|
| 2026-06-30 | $100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $300.00K 10-Q · filed 2026-08-06 | $400.00K derived: sum of 3 quarters · filed 2026-08-06 | $400.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $200.00K 10-Q · filed 2026-05-07 | $300.00K derived: sum of 2 quarters · filed 2026-05-07 | $300.00K derived: sum of 3 quarters · filed 2026-05-07 | $300.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $100.00K derived: sum of 2 quarters · filed 2026-02-26 | $100.00K derived: sum of 3 quarters · filed 2026-02-26 | $200.00K 10-K · filed 2026-02-26 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $0.00 derived: sum of 2 quarters · filed 2025-11-06 | $100.00K 10-Q · filed 2025-11-06 | $100.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $100.00K 10-Q · filed 2025-08-07 | $100.00K derived: sum of 3 quarters · filed 2025-08-07 | $200.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | $100.00K 10-Q · filed 2025-05-08 | $100.00K derived: sum of 2 quarters · filed 2025-05-08 | $200.00K derived: sum of 3 quarters · filed 2025-05-08 | -$200.00K derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $100.00K derived: sum of 2 quarters · filed 2025-02-27 | -$300.00K derived: sum of 3 quarters · filed 2025-02-27 | $500.00K 10-K · filed 2025-02-27 |
| 2024-09-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$300.00K derived: sum of 2 quarters · filed 2024-11-07 | $500.00K 10-Q · filed 2024-11-07 | $600.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | -$400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $400.00K 10-Q · filed 2024-08-08 | $500.00K derived: sum of 3 quarters · filed 2024-08-08 | $400.00K derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | $800.00K 10-Q · filed 2024-05-09 | $900.00K derived: sum of 2 quarters · filed 2024-05-09 | $800.00K derived: sum of 3 quarters · filed 2024-05-09 | $800.00K derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | $600.00K 10-K · filed 2024-02-28 |
| 2023-09-30 | -$100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$100.00K derived: sum of 2 quarters · filed 2023-11-08 | $500.00K 10-Q · filed 2023-11-08 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $600.00K 10-Q · filed 2023-08-07 | ||
| 2023-03-31 | $600.00K 10-Q · filed 2023-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |